The future of nutritional supplements is here, and its name is Vitaprotein.
Worried that your supplements aren’t giving you the nutrients that you need? With Vitaprotein’s patented technology, you can put those worries to rest.
Vitaprotein® is the product of over 20 years of molecular biological research spearheaded by Dr. Günter Blobel. Blobel is the esteemed German scientist and Nobel Prize awardee who developed Signal Theory, a remarkable discovery that singlehandedly revolutionized our modern understanding of how proteins are transported and assimilated throughout the body.
Vitaprotein supplements are the only line of nutritional products to use a biologically modified active carrier protein. Taking advantage of the so-called “post-code phenomenon” from Blobel’s research, Vitaprotein supplements are absorbed better by the body, making it the only brand of supplements in the world clinically proven to have double the effectiveness than your run-of-the-mill brands currently on the shelves.
Vitaprotein is the active ingredient of the Viproactive line of dietary supplements, manufactured and sold from Germany. Schaeffer Nutraceuticals, the people behind this revolutionary line of products, have long entered into their growth-phase through the constant demand of their supplements, both locally and online.
Schaeffer Nutraceuticals is an established German pharmaceutical company that specializes in the development of next-generation supplements using industry-leading research. At the moment, they are looking to generate capital to boost their research and development capabilities, especially now that they are looking to expand their current lineup of products. By partnering with TFGcrowd, they are looking to raise 100000€, and are willing to reward potential investors with a rate of 17%, to be paid out over the loan term of 8 months.
The following pledges secure the loan:
• A pledge on PROTO GLOBAL GmbH
• Personal guarantee of the Borrowers’ shareholders & CEO
• Guarantee of the Borrower
The loan is offered with the BuyBack Guarantee: thus, if a borrower is late with the repayment of the loan, TFGcrowd will compensate the investors both the invested principal amount and interest, as well as pay the accrued interest after 30 days of delay.
Schaeffer Nutraceuticals is one of TFGcrowd’s most attractive projects yet. A favorable market conditions, and an ever-growing demand for their segment – you can’t go wrong with Vitaprotein as your next best investment.
Germany has several advantages for pharmaceutical companies, such as its market size, a robust legal framework for approval and reimbursement, as well as the quality and cost-effectiveness of its clinical research. In 2015, the global pharmaceutical market was 1.07 trillion USD. The US has the largest market with 433 billion USD, second is China with 115 billion USD, third is Japan with 81 billion USD, and Germany has the world’s fourth largest market with 43 billion USD. The German market is Europe’s largest market. Germany ranks fourth in the world as a location for conducting clinical trials. It has a global market share of 6.7% for all clinical studies, following the US (44%), China (9.8%) and Canada (7.2%).
More recent data for both the pharmaceutical market reflect conditions that bode well for companies like Schaeffer Nutraceuticals. The influx of new technologies have also expanded the existing distribution channels for nutraceutical goods, for example, an online pharmacy sales have grown in 2-digit rates in 2016, which made up 12% of the German OTC drug market at the time. The German pharmaceutical industry is also expected to grow from its 52.9 billion EUR benchmark in 2016 to 67.2 billion by 2021 at a CAGR of 4.9%
The same could be said about one of Germany’s fastest-growing segments under its pharmaceutical industry, the nutrition and supplements market. Growing health consciousness among the local populace has generated a more or less stable demand for nutritional supplements, generating US$31.7 billion in 2016 alone, and is expected to grow at a CAGR of 5.9% through 2025. Along with France and Italy, the German nutraceuticals industry made up over 40% of the total sales of Europe.
The primary drivers for demand locally appear to be adult consumers, which made up around 39.8% of the gross revenue from 2016. Taken together, these insights prove that companies like Schaeffer Nutraceuticals are in a favorable position to take advantage of the continued growth of both the pharmaceutical industry as a whole and the nutrition and supplements segment in particular. Coupled with Vitaprotein’s promising prospects as a product, an investment on Schaeffer Nutraceuticals today is almost guaranteed to turn in significant profit with the right level of investment.